explore -WSS

explore

author：Wikipedia 2025-10-02 18:42:21 - browse：9117

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

WSS

Sophia Smith scores twice for US in in 3

National associations that represent hospice owe an apology

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

4 missing after record

PrEP can help anyone prevent HIV. Why do so few people take it?

How a key Senate committee is planning to regulate PBMs

entertainment

explore

explore

Malaria cases in Florida and Texas: Here’s what you need to know

What Henrietta Lacks's story taught me about my role as a doctor

What does generative AI mean for health care? We asked experts

Roche's accidental data boosts hopes for anti

Activists slam private health insurers over coverage restrictions

Where does female orgasm come from? Scientists think they know

Wildfire smoke exposes gaps in outdoor worker protections

DeSantis wants to import drugs. Biden’s FDA blasted his plan

BioMarin wins approval for gene therapy to treat hemophilia A

Intellia plays down concerns on accidental germline transmission

entertainment

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

How a key Senate committee is planning to regulate PBMs

As obesity drug market grows, telehealth companies court payers

National associations that represent hospice owe an apology

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

The response to Covid

focus

hotspot

hotspot

focus